Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery
· Medical Xpressby American Association for Cancer Research
edited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors responded to neoadjuvant immunochemotherapy (ICT) and who underwent less extensive surgery had high disease-free survival and organ preservation rates, according to a study published in Clinical Cancer Research, authored by Kunyu Yang, MD, director of Union Hospital Cancer Center at Tongji Medical College and Huazhong University of Science and Technology in China, and others.
Head and neck cancers are malignancies that arise in the nasal cavity, sinuses, lips, mouth, salivary glands, throat or larynx. The most common types begin in squamous cells in the oral cavity, pharynx or larynx. More than 60% of patients with HNSCC are diagnosed at the locally advanced stage and are at high risk of recurrence and metastasis. Outcomes are particularly poor for patients with HPV-negative HNSCC.
"Traditionally, patients with locally advanced HPV-negative HNSCC undergo either definitive chemoradiotherapy without surgery or radical surgery followed by radiotherapy," Yang said.
"Radical surgery—extensive surgery to remove the tumor and all surrounding tissues—for locally advanced HNSCC often results in organ dysfunction and facial disfigurement. Although chemoradiotherapy can preserve organs like the larynx and pharynx, long-term follow-up studies have shown it can cause severe toxicities such as dysphagia, feeding tube dependence and voice loss," Yang added.
"Thus, there remains a significant unmet need for improved treatment options, as these approaches continue to be associated with high recurrence rates and poor quality of life."
Testing a less extensive approach
Previous research has shown that adding immunotherapy to the treatment regimen for HNSCC improves overall survival. An earlier study by Yang's group, also published in Clinical Cancer Research, demonstrated that administering ICT before surgery and radiotherapy significantly improved outcomes for patients with locally advanced HNSCC.
"Because patients responded so well to neoadjuvant ICT and displayed profound tumor shrinkage, we next wanted to ask if this strategy could allow for less extensive surgery while still maintaining disease control and positive functional outcomes," Yang said.
To test this, Yang and his team treated 52 patients with HPV-negative, locally advanced, resectable HNSCC with three cycles of ICT. During neoadjuvant treatment, patients were monitored by imaging for tumor response.
Patients who had ≥50% tumor regression following ICT underwent reduced-volume surgery—a procedure that removes the residual tumor but aims to minimally affect nearby structures and organs—while those who had <50% tumor regression received standard-volume surgery.
Strong outcomes among responders
Forty-seven patients completed three cycles of neoadjuvant therapy and proceeded to surgery, while five patients did not continue with the study protocol. Among these 47 patients, 42 (90%) had tumors that shrank by ≥50% and underwent reduced-volume surgery. Five patients (10%) had <50% tumor regression after ICT and received standard-volume surgery.
At two years, 90% of patients who received reduced-volume surgical treatment remained free of recurrence, metastasis or death. Furthermore, laryngeal function was preserved in all 39 (100%) patients who presented with laryngeal or hypopharyngeal cancer and had reduced-volume surgery.
In contrast, patients who had <50% tumor regression and underwent standard-volume surgery had a two-year disease-free survival rate of only 20%. Complete loss of laryngeal function occurred in one of the three patients undergoing laryngeal or hypopharyngeal surgery.
PD-L1 may help predict benefit
The study also revealed that PD-L1 expression may serve as a potential predictive biomarker for response to ICT. Higher PD-L1 Combined Positive Score (CPS), a measure of PD-L1 expression, was positively correlated with improved pathological complete response (pCR) rates after neoadjuvant ICT. Among patients with a high PD-L1 CPS (>20), 65% had a pCR, compared with 28% of those with CPS 1–19 and 14% of those with CPS <1.
"Our results are promising and provide a strong rationale for further investigation," Yang said. "While they are not yet sufficient to change the current standard of care, we show that ICT before surgery resulted in remarkable tumor reduction and patient outcomes even with reduced-volume surgery.
"This suggests that surgery may be individually tailored based on tumor response to neoadjuvant ICT. These findings also suggest that resistance to early treatment may be a strong prognostic marker and highlight the urgent need for alternative therapeutic strategies for nonresponding cancers."
The study limitations include its single-arm design and relatively small sample, which consisted predominantly of laryngeal and hypopharyngeal cancers.
Publication details
Response-adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase 2 Trial, Clinical Cancer Research (2026). DOI: 10.1158/1078-0432.CCR-26-1337
Journal information: Clinical Cancer Research
Key medical concepts
Clinical categories
OncologyGeneral surgery Provided by American Association for Cancer Research Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery (2026, September 10) retrieved 10 September 2026 from https://medicalxpress.com/news/2026-09-tumor-response-immunochemotherapy-neck-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.